Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
Open Access
- 22 March 2020
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (9) , 1819-1826
Abstract
Aims: To identify, characterize and compare all Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals that included real‐world data on efficacy from expanded access (EA) programmes.Methods: Cross‐sectional study of FDA (1955–2018) and EMA (1995–2018) regulatory approval documentation. We automated searching for terms related to EA in 22,506 documents using machine learning techniques. We included all approvals where EA terms appeared in the regulatory documentation. Our main outcome was the inclusion of EA data as evidence of clinical efficacy. Characterization was based on approval date, disease area, orphan designation and whether the evidence was supportive or pivotal.Results: EA terms appeared in 693 out of 22,506 (3.1%) documents, which referenced 187 approvals. For 39 approvals, data from EA programmes were used to inform on clinical efficacy. The yearly number of approvals with EA data increased from 1.25 for 1993–2013 to 4.6 from 2014–2018. In 13 cases, these programmes formed the main evidence for approval. Of these, patients in EA programmes formed over half (median 71%, interquartile range: 34–100) of the total patient population available for efficacy evaluation. Almost all (12/13) approvals were granted orphan designation. In 8/13, there were differences between regulators in approval status and valuation of evidence. Strikingly, 4 treatments were granted approval based solely on efficacy from EA.Conclusion: Sponsors and regulators increasingly include real‐world data from EA programmes in the efficacy profile of a treatment. The indications of the approved treatments are characterized by orphan designation and high unmet medical need.Keywords
Funding Information
- myTomorrows
This publication has 25 references indexed in Scilit:
- Real-World Evidence — What Is It and What Can It Tell Us?New England Journal of Medicine, 2016
- Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year PeriodTherapeutic Innovation & Regulatory Science, 2016
- “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?Clinical Pharmacology & Therapeutics, 2016
- FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsClinical Cancer Research, 2016
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014BMJ Open, 2016
- Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam2015
- Compassionate use of orphan drugsOrphanet Journal of Rare Diseases, 2015
- Practical, Legal, and Ethical Issues in Expanded Access to Investigational DrugsNew England Journal of Medicine, 2015
- An Overview of the Tesseract OCR EngineNinth International Conference on Document Analysis and Recognition (ICDAR 2007), 2007
- The FDA's New Procedures for the Use of Investigational Drugs in TreatmentJAMA, 1988